ライフサイエンスコーパス: sulfadoxine

1 of the antifolate combination pyrimethamine/sulfadoxine.

2 d the impact of dhps genotype on response to sulfadoxine.

3 ays) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose); amo

4 ks were randomly assigned in blocks of 16 to sulfadoxine (250 mg) plus pyrimethamine (12.5 mg; n=319

5 dren were treated with either chloroquine or sulfadoxine\#8211;pyrimethamine and followed for 28 days

6 terval [CI], 93 to 100), and the efficacy of sulfadoxine\#8211;pyrimethamine was 21% (95% CI, 13 to 3

7 pared with 71 of 87 participants assigned to sulfadoxine\#8211;pyrimethamine.

8 stions about any policy to use pyrimethamine-sulfadoxine alone as the first-line treatment for malari

9 ard regimens of chloroquine or pyrimethamine-sulfadoxine alone or in combination with 1 or 3 doses of

10 her in the group that received pyrimethamine-sulfadoxine alone.

11 aged 6 months to 5 years to receive 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine plus either pla

12 s lowest in those who received pyrimethamine-sulfadoxine and 3 doses of artesunate, and it was 8-fold

13 t HIV(+) women received a dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine.

14 replace chloroquine with the combination of sulfadoxine and pyrimethamine for the treatment of malar

15 The pharmacokinetics of sulfadoxine and pyrimethamine were compared between thes

16 reening, prophylaxis with the combination of sulfadoxine and pyrimethamine, and treatment, as needed.

17 receive sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, and 1.25 mg/kg pyrimethamine) plus placebo;

18 Glu540 of DHPS was selected by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment, sh

19 iants is important for in vivo resistance to sulfadoxine in the area studied.

20 nthetase (DHPS), in the parasite response to sulfadoxine inhibition.

21 loroquine, and the combination pyrimethamine-sulfadoxine is the most commonly chosen alternative.

22 ks after treatment with either pyrimethamine-sulfadoxine or chlorproguanil-dapsone was analyzed for v

23 rve (AUC(0-->infinity)) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum

24 rtum status did have a significant affect on sulfadoxine pharmacokinetics.

25 fects of vitamin A and the antimalarial drug sulfadoxine pyramethamine (SP) on erythropoietin product

26 ria in infants aged 2-11 months, but neither sulfadoxine-pyrimethamine (-6.7%, -45.9 to 22.0) nor chl

27 thamine (44/125 [35%]) than with amodiaquine+sulfadoxine-pyrimethamine (12/129 [9%]; risk difference

28 for retreatment over 28 days for amodiaquine+sulfadoxine-pyrimethamine (17/129 [13%]) and amodiaquine

29 eive: chloroquine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg

30 re was significantly higher with chloroquine+sulfadoxine-pyrimethamine (44/125 [35%]) than with amodi

31 lorproguanil-dapsone was less effective than sulfadoxine-pyrimethamine (adjusted odds ratio [OR], 6.4

32 iving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy.

33 ermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of e

34 mittent preventive therapy in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

35 ived intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP).

36 hree or more (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).

37 3 days of amodiaquine (n=270), amodiaquine +sulfadoxine-pyrimethamine (n=507), or amodiaquine+artesu

38 ), or intermittent preventive treatment with sulfadoxine-pyrimethamine (n=515); 1368 (88%) women comp

39 d with increased risk of clinical failure of sulfadoxine-pyrimethamine (S/P).

40 patients treated with chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus

41 afety and efficacy of this drug with that of sulfadoxine-pyrimethamine (SP) as treatment for uncompli

42 t in infants (IPTi) is the administration of sulfadoxine-pyrimethamine (SP) at 2, 3, and 9 months of

43 ntive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malar

44 spectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 t

45 However, sulfadoxine-pyrimethamine (SP) efficacy is threatened by

46 Resistance to the antimalarial drug sulfadoxine-pyrimethamine (SP) emerged in Plasmodium fal

47 d Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventi

48 owever, parasites resistant to the IPTp drug sulfadoxine-pyrimethamine (SP) have emerged worldwide, a

49 artemisinin-piperaquine (DP) was superior to sulfadoxine-pyrimethamine (SP) in preventing maternal an

50 quine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalari

51 iparum genes Pfdhfr and Pfdhps have rendered sulfadoxine-pyrimethamine (SP) ineffective for malaria t

52 iveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-t

53 ffordable drugs such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) is a major global health

54 Sulfadoxine-pyrimethamine (SP) is among the most commonl

55 ntive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against mal

56 reventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malari

57 Sulfadoxine-pyrimethamine (SP) is used throughout Africa

58 n used bednets and received a single dose of sulfadoxine-pyrimethamine (SP) on enrollment, followed b

59 Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), gi

60 study of IPTp comparing the standard 2-dose sulfadoxine-pyrimethamine (SP) regimen with monthly IPTp

61 tations associated with chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance and the micros

62 Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan

63 In 2007, Malawi replaced sulfadoxine-pyrimethamine (SP) with an artemisinin-based

64 t 6 mo of age to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfa

65 were treated for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), o

66 revalence of malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recom

67 s included placebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), SP+amodiaquine, SP+piper

68 and is sometimes inadvertently treated with sulfadoxine-pyrimethamine (SP).

69 Es) following simultaneous administration of sulfadoxine-pyrimethamine (SP-IPTi) with immunizations,

70 year and location with treatment studies of sulfadoxine-pyrimethamine among symptomatic children.

71 ere is already a high level of resistance to sulfadoxine-pyrimethamine and amodiaquine.

72 area with a high prevalence of resistance to sulfadoxine-pyrimethamine and chloroquine.

73 a double-blind, placebo-controlled trial of sulfadoxine-pyrimethamine and chlorproguanil-dapsone tre

74 ommended antimalarials, such as Chloroquine, Sulfadoxine-Pyrimethamine and oral Artesunate monotherap

75 ttent preventive treatment with two doses of sulfadoxine-pyrimethamine and the use of insecticide-tre

76 ium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days

77 ntly evaluated as a potential alternative to sulfadoxine-pyrimethamine as intermittent preventive tre

78 ial of IPTi in an area of high resistance to sulfadoxine-pyrimethamine at sites of moderate (n=1280 i

79 Administration of sulfadoxine-pyrimethamine at times of vaccination-interm

80 IPTi with sulfadoxine-pyrimethamine did not have a clinically sign

81 INTERPRETATION: IPTi with sulfadoxine-pyrimethamine does not affect serological re

82 Nine trials of IPT with sulfadoxine-pyrimethamine during pregnancy in Africa wer

83 trials compared 2-dose with monthly IPT with sulfadoxine-pyrimethamine during pregnancy.

84 atment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months

85 cy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third tr

86 In areas in which 1 of 4 treatments with sulfadoxine-pyrimethamine fail in children by day 14, th

87 , Uganda, were treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplica

88 e is a promising alternative drug to replace sulfadoxine-pyrimethamine for intermittent preventive tr

89 ampala, Uganda were treated with amodiaquine+sulfadoxine-pyrimethamine for uncomplicated malaria.

90 n the intermittent preventive treatment with sulfadoxine-pyrimethamine group (15 [3%] of 457 women vs

91 misinin-piperaquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the t

92 atic malaria was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 p

93 ntal malaria was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the thre

94 By day 14, only 1 patient in the sulfadoxine-pyrimethamine group had parasites.

95 the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-d

96 quine group, 5 of 290 patients (1.7%) in the sulfadoxine-pyrimethamine group, and 27 of 272 patients

97 Sulfadoxine-pyrimethamine has been widely used as first-

98 IPTi with sulfadoxine-pyrimethamine has no benefit in areas of ver

99 vel resistance to the antifolate combination sulfadoxine-pyrimethamine have a common origin.

100 Schools were randomly assigned to treatment (sulfadoxine-pyrimethamine in combination with amodiaquin

101 ve to intermittent preventive treatment with sulfadoxine-pyrimethamine in the context of high sulfado

102 compared the effectiveness of daily CMX with sulfadoxine-pyrimethamine intermittent preventive treatm

103 pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermittent treatment), and t

104 asmodium falciparum to the antimalarial drug sulfadoxine-pyrimethamine is a result of extremely rare

105 Increasing resistance to sulfadoxine-pyrimethamine is leading to a decline in its

106 Resistance to sulfadoxine-pyrimethamine is now increasing, especially

107 Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the

108 ent preventive therapy during pregnancy with sulfadoxine-pyrimethamine monotherapy.

109 African country to replace chloroquine with sulfadoxine-pyrimethamine nationwide in response to high

110 Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral ma

111 rmine the effect of increasing resistance to sulfadoxine-pyrimethamine on the efficacy of IPT during

112 Combinations of amodiaquine and sulfadoxine-pyrimethamine or artesunate were significant

113 ytes and asexual parasites more rapidly than sulfadoxine-pyrimethamine or chlorproguanil-dapsone did.

114 We investigated whether IPTi with sulfadoxine-pyrimethamine or other antimalarial drug com

115 o evidence of an adverse effect of IPTi with sulfadoxine-pyrimethamine or other antimalarial drugs on

116 groups (18 and 15, respectively) than in the sulfadoxine-pyrimethamine or placebo groups (eight death

117 ther one dose of artesunate plus one dose of sulfadoxine-pyrimethamine or two placebos on three occas

118 mbination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was mo

119 We randomly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a

120 l in children by day 14, the 2-dose IPT with sulfadoxine-pyrimethamine regimen continues to provide s

121 iation was consistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 96% dihydrop

122 adoxine-pyrimethamine in the context of high sulfadoxine-pyrimethamine resistance and malaria transmi

123 egnant adolescents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread.

124 The effect did not vary by sulfadoxine-pyrimethamine resistance levels (range, 19%-

125 , 112 g; 95% CI, 19-205 g) over the range of sulfadoxine-pyrimethamine resistance tested (8%-39%).

126 Sulfadoxine-pyrimethamine resistance was defined as the

127 ern Kenya with high malaria transmission and sulfadoxine-pyrimethamine resistance.

128 f the intermittent preventive treatment with sulfadoxine-pyrimethamine strategy recommended by WHO is

129 In a control sulfadoxine-pyrimethamine study, the prevalence of ms476

130 ent kits, which enabled teachers to dispense sulfadoxine-pyrimethamine tablets according to national

131 Four trials compared 2-dose IPT with sulfadoxine-pyrimethamine to case management or placebo

132 Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during preg

133 mmendation for coadministration of IPTi with sulfadoxine-pyrimethamine to infants at the time of the

134 the "quintuple mutant") were associated with sulfadoxine-pyrimethamine treatment failure but not with

135 gly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and mo

136 uld be included among factors that determine sulfadoxine-pyrimethamine treatment outcome.

137 nfluence of HIV infection on the response to sulfadoxine-pyrimethamine treatment.

138 t preventive therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a higher b

139 clinical treatment failure with amodiaquine+sulfadoxine-pyrimethamine was balanced by a lower risk o

140 samples from 2368 children from sites where sulfadoxine-pyrimethamine was compared with placebo were

141 Sulfadoxine-pyrimethamine was first introduced for treat

142 Efficacy of IPT with sulfadoxine-pyrimethamine was lower among women using in

143 e as a determinant of treatment outcome with sulfadoxine-pyrimethamine was retrospectively studied in

144 Risk of treatment failure with chloroquine+sulfadoxine-pyrimethamine was unacceptably high.

145 Chloroquine and sulfadoxine-pyrimethamine were equivalent in efficacy at

146 d, assessor-blinded clinical trial comparing sulfadoxine-pyrimethamine with mefloquine IPTp.

147 ntimalarial intermittent preventive therapy (sulfadoxine-pyrimethamine) and insecticide-treated mosqu

148 ure to malaria prevention (ITNs or IPTp with sulfadoxine-pyrimethamine) in pregnancy and birth outcom

149 eaving 1904 individuals (934 placebo and 970 sulfadoxine-pyrimethamine) in the study.

150 % (95% CI, 21.1%-32.1%) for amodiaquine plus sulfadoxine-pyrimethamine, 17.4% (95% CI, 13.1%-23.1%) f

151 amodiaquine, 97 of 476 (20%) for amodiaquine+sulfadoxine-pyrimethamine, 54 of 491 (11%) for amodiaqui

152 of 3 combination therapies (amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate,

153 We compared chloroquine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrim

154 quine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, and amodiaquine+artesunate fo

155 ized controlled trial comparing chloroquine, sulfadoxine-pyrimethamine, and chlorproguanil-dapsone fo

156 in-piperaquine than among those who received sulfadoxine-pyrimethamine, and monthly treatment with di

157 with intermittent preventive treatment with sulfadoxine-pyrimethamine, intermittent preventive treat

158 However, with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed.

159 Molecular assays for monitoring sulfadoxine-pyrimethamine-resistant Plasmodium falciparu

160 rapid deterioration of the effectiveness of sulfadoxine-pyrimethamine.

161 e, or intermittent preventive treatment with sulfadoxine-pyrimethamine.

162 after artesunate-amodiaquine or amodiaquine-sulfadoxine-pyrimethamine.

163 lying decreased efficacy of amodiaquine plus sulfadoxine-pyrimethamine.

164 isinin combination therapy, chloroquine, and sulfadoxine-pyrimethamine.

165 imalarials such as chloroquine, quinine, and sulfadoxine-pyrimethamine.

166 ose); amodiaquine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine; or amodiaquine and artesunate

167 y 54% (95% CI 36-66, p<0.0001) compared with sulfadoxine/ pyrimethamine alone and by 37% (12-54, p=0.

168 eria occurred in 13 of 131 (10%) patients on sulfadoxine/ pyrimethamine, nine of 131 (7%) on amodiaqu

169 a, Uganda, were randomly assigned to receive sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, and 1.2

170 Sulfadoxine/pyrimethamine (Fansidar) is widely used in A

171 between specific alleles and the failure of sulfadoxine/pyrimethamine (S/P) to clear the erythrocyti

172 n a thick film of blood and was treated with sulfadoxine/pyrimethamine (SP), in accordance with natio

173 hamine was significantly more effective than sulfadoxine/pyrimethamine alone in children aged younger

174 Affordable alternative treatments include sulfadoxine/pyrimethamine and amodiaquine.

175 Treatment of malaria with sulfadoxine/pyrimethamine and of presumed bacterial infe

176 rimethamine, amodiaquine, and an amodiaquine/sulfadoxine/pyrimethamine combination for treatment of u

177 The amodiaquine/sulfadoxine/pyrimethamine combination was the most effec

178 days was significantly more frequent in the sulfadoxine/pyrimethamine group (38 of 215, 18%) compare

179 Sulfadoxine/pyrimethamine plus amodiaquine could be used

180 up (38 of 215, 18%) compared with either the sulfadoxine/pyrimethamine plus amodiaquine group (two of

181 After 28 and 42 days, patients in the sulfadoxine/pyrimethamine plus amodiaquine group were si

182 Overall, sulfadoxine/pyrimethamine plus amodiaquine reduced the r

183 diaquine group (two of 164, 1%; p<0.0001) or sulfadoxine/pyrimethamine plus artesunate group (one of

184 ne and by 37% (12-54, p=0.007) compared with sulfadoxine/pyrimethamine plus artesunate.

185 Expanding use of sulfadoxine/pyrimethamine to treat chloroquine-resistant

186 Amodiaquine/sulfadoxine/pyrimethamine was significantly more effecti

187 /pyrimethamine, amodiaquine, and amodiaquine/sulfadoxine/pyrimethamine were all effective for treatme

188 Sulfadoxine/pyrimethamine, amodiaquine, and amodiaquine/

189 We compared the efficacy of sulfadoxine/pyrimethamine, amodiaquine, and an amodiaqui

190 Children <5 years old treated with sulfadoxine/pyrimethamine, cotrimoxazole, or no antimicr

191 In sulfadoxine/pyrimethamine-treated children, the proporti

192 iaquine, and four of 138 (3%) on amodiaquine/sulfadoxine/pyrimethamine.

193 (25 mg/kg) plus placebo; or amodiaquine plus sulfadoxine/pyrimethamine.

194 540 correlated with increased pyrimethamine-sulfadoxine resistance (P < .05).

195 teroate synthase gene (dhps) associated with sulfadoxine resistance and 5 microsatellite loci flankin

196 were common in Bolivia, where pyrimethamine-sulfadoxine resistance is widespread, but absent in Afri

197 esistance) preceded that of the dhps allele (sulfadoxine resistance).

198 e synthase (DHPS) and clinical pyrimethamine-sulfadoxine resistance, polymerase chain reaction survey

199 cular surveillance methods for pyrimethamine-sulfadoxine resistance.

200 spectively associated with pyrimethamine and sulfadoxine resistance.

201 e a watershed for haplotypes associated with sulfadoxine resistance.

202 ries with increasing levels of pyrimethamine-sulfadoxine resistance: Mali, Kenya, Malawi, and Bolivia

203 oyed to identify a clear correlation between sulfadoxine-resistance levels and the number of DHPS mut

204 ross between sulfadoxine-sensitive (HB3) and sulfadoxine-resistant (Dd2) parents.

205 DHPS) confer resistance to pyrimethamine and sulfadoxine, respectively.

206 in the 16 progeny of a genetic cross between sulfadoxine-sensitive (HB3) and sulfadoxine-resistant (D

207 nts to replace chloroquine and pyrimethamine/sulfadoxine threatens efforts to control the spread of d

208 ng prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed